Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
申请人:——
公开号:US20020006932A1
公开(公告)日:2002-01-17
The invention relates to compounds of the formula
1
wherein
R
1
is hydrogen, lower alkyl, lower alkenyl, phenyl or the following groups —(CH
2
)
m
-non aromatic heterocyclyl, which is optionally substituted by lower alkyl, or is —(CH
2
)
m
-heteroaryl, which is optionally substituted by one or two substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, CF
3
, benzyl or cyano, or is —(CH
2
)
m
—C(O)—NRR′, —(CH
2
)
m
—C(O)-lower alkyl, —(CH
2
)
m
—C(O)—O-lower alkyl, —(CH
2
)
m
—O-lower alkyl, —(CH
2
)
m
—CH[C(O)—O-lower alkyl]
2
, —(CH
2
)
m
CH(OH)—CH
2
—O-phenyl, —(CH
2
)
m
—CH(CF
3
)OH, —(CH
2
)
m
—OH, —(CH
2
)
m
—CN, —(CH
2
)
m
—NRR′, —(CH
2
)
m
-cycloalkyl or —(CH
2
)
m
—CHF
2
;
R
2
is hydrogen, lower alkyl, halogen or lower alkoxy;
R
3
is lower alkyl, lower alkoxy, halogen or CF
3
;
R,R′ are the same or different and are hydrogen or lower alkyl;
X is >N—, >C═ or >CH—;
X
1
/X
2
are independently from each other hydrogen, hydroxy or lower alkoxy or may be together an oxo group;
Y
1
/Y
2
are independently from each other hydrogen, lower alkyl, —CH
2
)
m
-phenyl or may be together an oxo group;
Z is a bond, —CH
2
— or —C(O)—;
m is 0, 1,2, 3 or 4;
n is 2 or 3;
n′ 0, 1 or 2;
and pharmaceutically acceptable acid addition salts thereof. The described compounds have a good affinity to the NK1 receptor.
该发明涉及以下式的化合物:
其中
R
1
为氢、低烷基、低烯基、苯基或以下基团之一 —(CH
2
)
m
-非芳杂环烷基,该基团可选择地被低烷基取代,或为 —(CH
2
)
m
-杂芳基,该基团可选择地被从以下基团中选择的一个或两个取代基取代,所述基团包括低烷基、低烷氧基、卤素、CF
3
、苄基或氰基,或为 —(CH
2
)
m
—C(O)—NRR′、—(CH
2
)
m
—C(O)-低烷基、—(CH
2
)
m
—C(O)—O-低烷基、—(CH
2
)
m
—O-低烷基、—(CH
2
)
m
—CH[C(O)—O-低烷基]
2
、—(CH
2
)
m
CH(OH)—CH
2
—O-苯基、—(CH
2
)
m
—CH(CF
3
)OH、—(CH
2
)
m
—OH、—(CH
2
)
m
—CN、—(CH
2
)
m
—NRR′、—(CH
2
)
m
-环烷基或—(CH
2
)
m
—CHF
2
;
R
2
为氢、低烷基、卤素或低烷氧基;
R
3
为低烷基、低烷氧基、卤素或CF
3
;
R、R′相同或不同,为氢或低烷基;
X为>N—、>C═或>CH—;
X
1
/X
2
独立地为氢、羟基或低烷氧基,或者可以一起是一个氧基团;
Y
1
/Y
2
独立地为氢、低烷基、—CH
2
)
m
-苯基,或者可以一起是一个氧基团;
Z为键、—CH
2
—或—C(O)—;
m为0、1、2、3或4;
n为2或3;
n′为0、1或2;
以及其药学上可接受的酸盐。所述化合物对NK1受体具有良好的亲和力。